

# Psychiatric disorders and subsequent risk of cardiovascular disease: a longitudinal matched cohort study across three countries



Qing Shen,<sup>a,b,c,\*</sup> Dorte Helenius Mikkelsen,<sup>d</sup> Laura Birgit Luitva,<sup>e</sup> Huan Song,<sup>c,f,g,h</sup> Silva Kasela,<sup>e</sup> Thor Aspelund,<sup>f</sup> Jacob Bergstedt,<sup>c,i</sup> Yi Lu,<sup>j</sup> Patrick F. Sullivan,<sup>ij</sup> Weimin Ye,<sup>i</sup> Katja Fall,<sup>c,k</sup> Per Tornvall,<sup>l</sup> Yudi Pawitan,<sup>i</sup> Ole A. Andreassen,<sup>m,n</sup> Alfonso Buil,<sup>o,p</sup> Lili Milani,<sup>e</sup> Fang Fang,<sup>cr</sup> and Unnur Valdimarsdóttir<sup>c,f,q,r,\*\*</sup>



<sup>a</sup>Clinical Research Center for Mental Disorders, Shanghai Pudong New Area Mental Health Center, Tongji University School of Medicine, Shanghai, China

<sup>b</sup>Institute for Advanced Study, Tongji University, Shanghai, China

<sup>c</sup>Unit of Integrative Epidemiology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden

<sup>d</sup>Institute of Biological Psychiatry, Mental Health Services Copenhagen, Copenhagen University Hospital, Copenhagen, Denmark

<sup>e</sup>Estonian Genome Centre, Institute of Genomics, University of Tartu, Tartu, Estonia

<sup>f</sup>Centre of Public Health Sciences, Faculty of Medicine, University of Iceland, Reykjavík, Iceland

<sup>g</sup>West China Biomedical Big Data Center, West China Hospital, Sichuan University, Chengdu, China

<sup>h</sup>Medical Big Data Center, Sichuan University, Chengdu, China

<sup>i</sup>Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden

<sup>j</sup>Departments of Genetics and Psychiatry, University of North Carolina, Chapel Hill, United States

<sup>k</sup>Clinical Epidemiology and Biostatistics, School of Medical Sciences, Örebro University, Örebro, Sweden

<sup>l</sup>Department of Clinical Science and Education Södersjukhuset, Karolinska Institutet, Stockholm, Sweden

<sup>m</sup>NORMENT Centre, Division of Mental Health and Addiction, Oslo University Hospital, Oslo, Norway

<sup>n</sup>Institute of Clinical Medicine, University of Oslo, Oslo, Norway

<sup>o</sup>PSYCH, The Lundbeck Foundation Initiative for Integrative Psychiatric Research, Aarhus, Denmark

<sup>p</sup>Mental Health Center Sct. Hans, Mental Health Services, Capital Region Denmark, Roskilde, Denmark

<sup>q</sup>Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, United States

## Summary

**Background** Several psychiatric disorders have been associated with increased risk of cardiovascular disease (CVD), however, the role of familial factors and the main disease trajectories remain unknown.

**Methods** In this longitudinal cohort study, we identified a cohort of 900,240 patients newly diagnosed with psychiatric disorders during January 1, 1987 and December 31, 2016, their 1,002,888 unaffected full siblings, and 1:10 age- and sex-matched reference population from nationwide medical records in Sweden, who had no prior diagnosis of CVD at enrolment. We used flexible parametric models to determine the time-varying association between first-onset psychiatric disorders and incident CVD and CVD death, comparing rates of CVD among patients with psychiatric disorders to the rates of unaffected siblings and matched reference population. We also used disease trajectory analysis to identify main disease trajectories linking psychiatric disorders to CVD. Identified associations and disease trajectories of the Swedish cohort were validated in a similar cohort from nationwide medical records in Denmark (N = 875,634 patients, same criteria during January 1, 1969 and December 31, 2016) and in Estonian cohorts from the Estonian Biobank (N = 30,656 patients, same criteria during January 1, 2006 and December 31, 2020), respectively.

**Findings** During up to 30 years of follow-up of the Swedish cohort, the crude incidence rate of CVD was 9.7, 7.4 and 7.0 per 1000 person-years among patients with psychiatric disorders, their unaffected siblings, and the matched reference population. Compared with their siblings, patients with psychiatric disorders experienced higher rates of CVD during the first year after diagnosis (hazard ratio [HR], 1.88; 95% confidence interval [CI], 1.79–1.98) and thereafter (1.37; 95% CI, 1.34–1.39). Similar rate increases were noted when comparing with the matched reference population. These results were replicated in the Danish cohort. We identified several disease trajectories

eClinicalMedicine  
2023;61: 102063

Published Online xxx  
<https://doi.org/10.1016/j.eclinm.2023.102063>

\*Corresponding author. Clinical Research Center for Mental Disorders, Shanghai Pudong New Area Mental Health Center, Tongji University School of Medicine, Shanghai, China.

\*\*Corresponding author. Unit of Integrative Epidemiology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.

E-mail addresses: [qing.shen@ki.se](mailto:qing.shen@ki.se) (Q. Shen), [unnurav@hi.is](mailto:unnurav@hi.is) (U. Valdimarsdóttir).

<sup>r</sup>Equal contribution.

linking psychiatric disorders to CVD in the Swedish cohort, with or without mediating medical conditions, including a direct link between psychiatric disorders and hypertensive disorder, ischemic heart disease, venous thromboembolism, angina pectoris, and stroke. These trajectories were validated in the Estonian Biobank cohort.

**Interpretation** Independent of familial factors, patients with psychiatric disorders are at an elevated risk of subsequent CVD, particularly during first year after diagnosis. Increased surveillance and treatment of CVDs and CVD risk factors should be considered as an integral part of clinical management, in order to reduce risk of CVD among patients with psychiatric disorders.

**Funding** This research was supported by EU Horizon 2020 Research and Innovation Action Grant, European Research Council Consolidator grant, Icelandic Research fund, Swedish Research Council, US NIMH, the Outstanding Clinical Discipline Project of Shanghai Pudong, the Fundamental Research Funds for the Central Universities, and the European Union through the European Regional Development Fund; the Research Council of Norway; the South-East Regional Health Authority, the Stiftelsen Kristian Gerhard Jebsen, and the EEA-RO-NO-2018-0535.

**Copyright** © 2023 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

**Keywords:** Psychiatric disorders; Cardiovascular disease; Sibling; Family design; Disease trajectory

#### Research in context

##### Evidence before this study

We searched PubMed for studies on the association between various clinically diagnosed psychiatric disorders and subsequent cardiovascular disease of any type, from database inception to November 15, 2022, using search terms “psychiatric/mental”, “cardiovascular”, and “cohort/prospective/longitudinal”, with restrictions on journal articles. We summarized the evidence from these 47 studies (in [Supplementary Material](#)) which mostly reported a positive association between depression, anxiety and stress-related disorders, and hypertension, coronary heart disease and stroke. These studies were often limited to selected populations (conscripts), with self-reported data and incomplete follow-up. Importantly, the role of unmeasured confounding factors on the observed associations between diagnosed psychiatric disorders and cardiovascular disease, in particular familial factors (i.e., genetic susceptibility and early-life environmental factors shared within families), were not firmly addressed in these studies. No study has so far assessed the disease trajectories linking common psychiatric disorders and cardiovascular diseases, limiting our understanding of pathophysiological mechanisms whether the link between the two disease groups was direct or mediated through other medical conditions (i.e., indirect link).

##### Added value of this study

With nationwide complete information on family links in Sweden and Denmark, our study is the first to comprehensively investigate the role of familial factors in the association between psychiatric disorders and subsequent risk of incident cardiovascular disease through a sibling

comparison. We demonstrated that independent of familial background, patients with psychiatric disorders had an increased risk of cardiovascular disease, with risk increment upmost during first year after psychiatric diagnosis and remained elevated up to thirty years of follow-up. We further identified several disease trajectories linking psychiatric disorders to cardiovascular disease in the Swedish cohort, with and without mediating medical conditions. The direct link between psychiatric disorders and hypertensive disorder, ischemic heart disease, venous thromboembolism, angina pectoris, and stroke, were independently validated in Estonian Biobank.

##### Implications of all the available evidence

Despite of the increasing knowledge on genetic correlations between several psychiatric disorders and cardiovascular diseases, our study provides solid evidence on the association between a wide range of psychiatric disorders and risk of incident cardiovascular disease and fatal cardiovascular events independent on shared familial factors, in Sweden and Denmark. The highest association noted during the first year after psychiatric diagnosis supports for an increased surveillance of cardiovascular comorbidities among newly diagnosed patients receiving a psychiatric diagnosis and highlight a critical time window for clinical management. The findings on several disease trajectories between psychiatric disorders and a list of cardiovascular diseases in Sweden and Estonian Biobank, contributing to a better understanding of the mechanisms underlying the development of cardiovascular disease following psychiatric disorders.

## Introduction

Patients with psychiatric disorders are at higher risk of various medical conditions<sup>1</sup> and premature death.<sup>2</sup> The latter has predominantly been attributed to cardiovascular disease (CVD).<sup>3,4</sup> We summarized 47 longitudinal cohort studies that investigated the association of various clinically diagnosed psychiatric disorders with selected CVDs (Appendix Table S1), mostly reporting positive associations. In addition to the often selected, healthy study populations (male or female conscripts),<sup>5–8</sup> self-reported data,<sup>9,10</sup> and incomplete follow-up,<sup>5,6,11,12</sup> the role of familial confounding was rarely addressed in the existing studies, except for two studies focusing on patients with anxiety or stress-related disorders.<sup>13,14</sup> Considering the genetic correlation between psychiatric disorders and CVD<sup>15</sup> as well as the importance of early life environment to the development of these two complex disease groups,<sup>16,17</sup> it is plausible that the comorbidity between the two groups of diseases is partially attributed to unmeasured genetic and environmental factors shared within families (i.e., familial confounding).<sup>18</sup> Thus, further studies are needed to assess the association between psychiatric disorders and CVD after accounting for familial confounding.

Further, the complex mechanisms and disease trajectories through which CVD develops in patients with psychiatric disorders has received little research attention.<sup>19</sup> Exploration of disease trajectories may help improve our understanding of the underlying mechanisms. Disease trajectory analysis has recently been established as an approach to explore disease progression.<sup>20,21</sup> One example is our recent study investigating the trajectories of medical conditions after a diagnosis of depression using disease network analysis, revealing cardiometabolic diseases, chronic inflammatory diseases, and diseases related to tobacco abuse, as main disease clusters following a diagnosis of depression.<sup>22</sup> Some disease clusters were directly linked to depression (i.e., a direct disease pathway) whereas other subsequent diseases were mediated through other medical conditions (i.e., an indirect disease pathway). To the best of our knowledge, the disease trajectories linking other common psychiatric disorders and CVD remain to be explored.

Leveraging the nationwide registers in Sweden and Denmark with the possibilities for family-based comparisons and controlling for multiple covariates and comorbid conditions, we aimed to investigate the role of familial factors in the association between all psychiatric disorders and subsequent risk of incident CVD. In order to improve our understanding of the directionality and disease progression, we further aimed to identify direct as well as indirect disease trajectories linking psychiatric disorders to CVD, exploring all common medical conditions following a diagnosis of psychiatric disorder in Sweden and validated the identified trajectories in the Estonian Biobank.

## Methods

### Study design

Using personal identification numbers uniquely assigned to all Swedish residents, we identified 963,585 individuals born after 1932 in Sweden who received a first diagnosis of any psychiatric disorder between 1 January 1987 and 31 December 2016.<sup>23</sup> Patients diagnosed with psychiatric disorders under age 1 (N = 3885, possible congenital/developmental anomalies) or with a prevalent CVD before diagnosis of psychiatric disorders (N = 59,460) were excluded, leaving 900,240 patients with a newly diagnosed psychiatric disorder in the analysis (Fig. 1). Date of first diagnosis of psychiatric disorder was used as the index date for the exposed patients.

The Swedish Multi-Generation Register includes largely complete familial linkage with information on mothers for 97% and on fathers for 95% of individuals born since 1932 and alive on January 1st 1961.<sup>24</sup> Through the Register, we identified 1,002,888 unaffected full siblings for 619,289 patients with psychiatric disorders (68.8% of all exposed patients) who were alive and free of psychiatric disorders and CVD before diagnosis of the index patient. For each exposed patient, we randomly selected 10 age- and sex-matched individuals from the study base using the method of incidence density sampling (N = 9,002,400).<sup>25</sup> This method aims to select a control group that mimics closely the underlying source population from which the exposed individuals arise. The date of diagnosis for the index patient was used as the index date for the unaffected siblings and matched reference population.

We followed all study participants from the index date until first diagnosis of any CVD, death, emigration, first diagnosis of psychiatric disorders (for unaffected siblings and matched reference population), or the end of the study period (31 December 2016), whichever occurred first.

The study was approved by the Ethical Vetting Board in Stockholm, Sweden (DNRs 2012/1814-31/4 and 2015/1062-32), the Danish Health Data Authority (project no. FSEID-00003339) and the Estonian Committee on Bioethics and Human Research (24 March 2020, nr 1.1-12/624).

### Ascertainment of psychiatric disorders and cardiovascular disease

We used the 9th and 10th Swedish revisions of the International Classification of Diseases (ICD-9 and 10) codes to identify psychiatric disorders and CVD attended by specialized care (Appendix Table S2). From the Swedish Patient Register, we defined incident psychiatric disorders as any first inpatient or outpatient hospital visit with a psychiatric disorder as the primary diagnosis. CVD was ascertained as any first inpatient or outpatient visit with CVD as the primary diagnosis (from the Patient Register), or as a death with CVD as



**Fig. 1: Flowchart of study design and study participants for Swedish cohort.** \*57,779 families had more than one sibling with psychiatric disorders.

the underlying cause (from the Causes of Death Register). The diagnostic accuracy of CVD is generally considered reliable in the Patient Register. We also identified fatal cardiovascular event as any death within 30 days of incident CVD according to the Causes of Death Register.

We classified psychiatric disorders as non-affective psychotic disorders, affective psychotic disorders, substance misuse, non-psychotic mood disorder, anxiety, and stress-related disorders, eating disorder, personality disorders, attention deficit hyperactivity disorder (ADHD), autism spectrum disorder (ASD), and intellectual disability.<sup>26</sup> Consistent with our previous work,<sup>14</sup> we categorized CVD as ischemic heart disease, cerebrovascular disease, emboli and thrombosis, hypertensive disease, heart failure, and arrhythmia/conduction disorder.

#### Covariates

We obtained educational level, individualized family income, and cohabitation status from the Longitudinal Integration Database for Health Insurance and Labor Market.<sup>27</sup> Participants with missingness on these variables were grouped as unknown or missing for categorical variables. Having any of the following conditions before the index date was defined as having a history of somatic diseases: chronic pulmonary disease,

connective tissue disease, diabetes, renal diseases, liver disease, ulcer diseases, malignancies, and HIV infection/AIDS (Appendix Table S2). We considered a family history of CVD as a diagnosis of any CVD or death from CVD among biological parents or full siblings of the study participants before the index date according to the Swedish Patient Register and Causes of Death Register.

#### Statistical analysis

The statistical analysis includes two steps, namely association analysis and disease trajectory analysis. In each step, we designed an exploration phase in the Swedish cohort and a replication/validation phase in Denmark and Estonian Biobank, respectively (Appendix Figure S2).

#### Association analysis

To visualize the temporal patterns of the association between psychiatric disorders and CVD, we used flexible parametric models to estimate the time-varying hazard ratio of incident CVD following a diagnosis of psychiatric disorders,<sup>28</sup> by comparing the hazard of CVD in patients with psychiatric disorders to the hazard in their unaffected full siblings and matched reference population. Because we observed a marked increase of CVD rate immediately following a diagnosis of psychiatric disorders, we separately estimated the association

within one year and beyond one year after diagnosis. We estimated the averaged hazard ratio and 95% confidence intervals (CIs) during the first year of follow-up and beyond, from stratified Cox models, using time since the index date as the underlying time scale. The proportional hazard assumption was tested using Schoenfeld residuals and found to hold. HRs were estimated for any event of first-onset CVD and by categories of this first-onset CVD. Because patients with psychiatric disorders are frequently diagnosed with multiple psychiatric disorders, in the analysis by groups of psychiatric disorders, we identified all diagnoses of psychiatric disorders during follow-up and considered psychiatric disorders as a time-varying variable. Patients contributed person-time to different psychiatric disorders after the first diagnosis of the respective psychiatric disorder, if more than one diagnosis of psychiatric disorders were registered after cohort entry.

We performed subgroup analyses by sex, age at index date (by tertile distribution:  $\leq 22$ , 23–41, or  $\geq 42$  years), age at follow-up ( $< 35$  or  $\geq 35$  years), calendar year at index date (1987–1996, 1997–2006, or 2007–2016), history of somatic diseases (no or yes), and family history of CVD (no or yes). In the sibling comparison, Cox models were stratified by family identifier and adjusted for sex, birth year, educational level, individualized family income, cohabitation status, and history of somatic diseases. In the population comparison, Cox models were stratified by the matching variables (birth year and sex) and adjusted for all abovementioned covariates plus family history of CVD.

#### *Replication of the association analysis in a Danish cohort*

To assess whether the associations identified in the Swedish cohort could be generalized to an external population, we applied the same approach and identified a Danish cohort including 875,634 patients with first-onset psychiatric disorders, their unaffected full siblings ( $N = 625,710$ , among 46.1% of the patients with psychiatric disorders), and up to 1:10 age- and sex-matched reference population ( $N = 8,756,340$ ). Details on study design are available in [Appendix Figure S1 and Section 1](#).

#### *Disease trajectory analysis*

To identify disease trajectories following a diagnosis of first-onset psychiatric disorder, we applied disease trajectory analysis to explore all medical conditions diagnosed subsequent to a diagnosis of psychiatric disorders.<sup>20,21</sup> This analysis was performed among patients with psychiatric disorders diagnosed between 2001 and 2016, due to the availability of outpatient records from 2001 onward in the Swedish Patient Register.<sup>23</sup> We used the 3-digit ICD-10 codes for medical condition identification and clustered conditions with clinical or biological similarities.<sup>21</sup> To minimize concerns of reverse causality, we included only medical

conditions diagnosed more than six months after the diagnosis of psychiatric disorders.

The disease trajectory analysis is exploratory in nature with the aim to better understand the link between psychiatric disorders and subsequent CVDs. It included three steps: 1) we identified all subsequent medical conditions associated with a diagnosis of psychiatric disorder in a phenome-wide association analysis (PheWAS), by comparing patients with psychiatric disorders to matched population controls; 2) we determined the temporal order of the following two diseases in the trajectory among patients with a psychiatric disorder. To explore trajectories leading to any CVD, either disease 1 or disease 2 was restricted to be CVD; and 3) we assessed the magnitude of the association between the two diseases within each pair using conditional logistic regression (details in [Appendix Section 2](#)). Because the disease trajectory analysis explored two medical conditions following psychiatric disorders, per trajectory (e.g., psychiatric disorder to disease 1 [D1] to disease 2 [D2]), we concluded on a direct link between psychiatric disorder and CVD if D1 was any CVD, and referred to an indirect link if D2 was any CVD. The disease trajectory analysis was performed for all groups of psychiatric disorders except for ASD, due to the lack of associations between ASD and CVD in the association analysis.

#### *Validation of the disease trajectory analysis in Estonian Biobank (EstBB)*

EstBB is a population-based biobank at the Institute of Genomics at the University of Tartu with participants representing 20% adult population in Estonia.<sup>29</sup> To validate if the disease trajectories identified in the Swedish cohort were generalizable to an external population, we constructed a matched cohort in EstBB comprising 30,656 patients with psychiatric disorders and up to 1:10 age- and sex-matched reference population to examine the identified direct disease pathways between psychiatric disorders and subsequent CVD. Detailed description of the EstBB database, construction of the validation cohorts, and analytical methods are available in [Appendix Section 3](#).

Analyses were performed in SAS 9.4 (SAS Institute), STATA 16 (StataCorp LP) and R (version 4.1.2). Informed consent was waived by law using register-based data for the Swedish and Danish participants, and was provided by each participant in the Estonian Biobank at enrollment. Our study is reported according to the Strengthening the Reporting of Observational studies in Epidemiology checklist (STROBE) reporting guideline.

#### **Role of the funding source**

The funder of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. QS, FF and UV had full access to the Swedish data, DHM and AB had full access to the



Danish data, and LBL, SK and LM had full access to the Estonian data in the study, and take responsibility for the integrity and the accuracy of the data in the respective cohort. The corresponding authors had final responsibility for the decision to submit for publication, upon the approval from all authors.

## Results

### Association analysis

In the Swedish cohort, the median age of patients with psychiatric disorders was 28 years (Table 1), varying from 12 years for ASD to 39 years for affective psychotic disorder (Appendix Table S3). Although similar, patients with psychiatric disorders of the sibling comparison were younger than those of the population comparison (26 vs. 28 years). The population was similar in the Danish cohort (Appendix Table S4).

During up to 30 years of follow-up in the Swedish cohort, the crude incidence rate of any CVD was 9.7, 7.4, and 7.1 per 1000 person-years among the patients with psychiatric disorders, their unaffected full siblings, and matched reference population (Appendix Table S5). In the sibling comparison, we found a marked increase in risk of CVD shortly after a diagnosis of psychiatric disorders, which then declined gradually over time (Fig. 2): the HR was 1.88 (95% CI 1.79–1.98) within first year and 1.37 (95% CI 1.34–1.39) beyond first year after diagnosis (Appendix Table S6). Similar rate increases were noted when comparing to matched reference population (HR 1.91 [95% CI 1.86–1.96] within first year and 1.41 [95% CI 1.40–1.43] beyond first year since diagnosis). We observed similar associations by sex, age, calendar year, history of somatic diseases, or family history of CVD (Appendix Table S5).

A higher rate was noted for most categories of CVD, including fatal cardiovascular events, within and beyond first year since diagnosis of psychiatric disorders (Fig. 3; Appendix Table S7). We found a higher rate of CVD for most groups of psychiatric disorders except for ASD (Fig. 4), with the greatest rate increase observed for eating disorder, particularly anorexia nervosa (Appendix Table S8). Similar rate increases were observed in all categories of CVD in the Danish cohort (Fig. 3).

### Disease trajectory analysis

We identified 42 disease trajectories linking psychiatric disorders with subsequent CVD (Appendix Section 4). We found a direct disease pathway between psychiatric disorders and subsequent to hypertensive disorder, ischemic heart disease, venous thromboembolism, angina pectoris, and stroke (i.e., no intermediate diseases identified between these two) (Appendix Figure S3). These pathways were all validated in EstBB with largely similar magnitude of the associations (Fig. 5). Mediated by other medical conditions, we also found an indirect disease pathway between psychiatric disorders and heart

failure, cardiac arrhythmia, endocarditis, cardiomyopathy, mediated through different medical conditions (Appendix Figure S3). When analyzing subgroups of psychiatric disorders, we found overall similar pattern of results, although lower number of disease pathways were observed (Appendix Figure S4).

## Discussion

Leveraging a large nationwide cohort of two countries including virtually all patients diagnosed with a psychiatric disorder over a 30-year period, their unaffected full siblings and a set of randomly selected population comparison groups, our study demonstrates a robust association between psychiatric disorders and subsequent risk of incident CVD, independent of familial factors and somatic comorbidities. The highest rate increment was noted during the first year after diagnosis, indicating a high-risk time window for clinical surveillance. Further, we identified a total of 42 disease trajectories linking psychiatric disorders to CVD, including a direct link between psychiatric disorders and hypertensive disorders, ischemic heart disease, venous thromboembolism, angina pectoris, and stroke. The associations were replicated in a Danish nationwide cohort whereas the disease trajectories were validated in the Estonian Biobank.

Our study is the first to comprehensively assess the association between all common psychiatric disorders and CVD with vigorous control of familial factors and comorbidities. Our findings confirm the results from the existing literature, suggesting a positive association between specific psychiatric disorders and CVD. For instance, previous studies and several meta-analyses have reported an increased risk of selected CVDs among patients with depression,<sup>30</sup> anxiety,<sup>31</sup> and PTSD.<sup>32</sup> With few exceptions,<sup>13,14,33</sup> these studies have, however, not addressed the role of familial factors in the associations. Previous studies have reported a positive association between obsessive-compulsive disorder as well as stress-related disorders and CVD, independent of familial confounding.<sup>13,14,33</sup> Our study therefore extends the existing knowledge base by demonstrating robust associations, between a wide range of psychiatric disorders and subsequent risk of incident CVD and fatal CVD events, independent of shared familial factors. We further showed that the excess rates of CVD after diagnosis of psychiatric disorders was persistent up to 30 years, although the highest risk increase was observed during the first year. Increased medical surveillance may partly explain the risk increase for some of the CVD outcomes, e.g., hypertension, during the immediate time period after diagnosis of psychiatric disorders. It is however unlikely to explain the risk increase of most other acute and severe CVD outcomes which often require immediate medical attention and of fatal CVD events.

Characteristics	Sibling comparison			Population comparison		
	Exposed patients (N = 619,289)	Unaffected full siblings (N = 1,002,888)	P value	Exposed patients (N = 900,240)	Matched reference population (N = 9,002,400)	P value
Median age at index date in years (IQR)	26.00 (18.00–42.00)	28.00 (18.00–44.00)	<0.0001	28.00 (18.00–44.00)	28.00 (18.00–44.00)	–
Median follow-up time in years (IQR)	7.96 (3.78–12.85)	7.88 (3.62–13.08)	<0.0001	7.79 (3.68–12.70)	7.58 (3.53–12.67)	<0.0001
Sex						
Female	320,594 (51.77)	489,919 (48.85)	<0.0001	465,819 (51.74)	4,658,190 (51.74)	–
Male	298,695 (48.23)	512,969 (51.15)	<0.0001	434,421 (48.26)	4,344,210 (48.26)	–
Educational level						
<9 years	186,406 (30.10)	271,251 (27.05)	<0.0001	278,718 (30.96)	1,969,745 (21.88)	<0.0001
9–12 years	267,590 (43.21)	439,550 (43.83)		389,953 (43.32)	3,937,777 (43.74)	
>12 years	165,293 (26.69)	292,087 (29.12)		231,569 (25.72)	3,094,878 (34.38)	
Yearly individualized family income level						
Top 20%	100,837 (16.28)	223,287 (22.26)	<0.0001	123,287 (13.69)	1,856,114 (20.62)	<0.0001
Middle	400,273 (64.63)	571,858 (57.02)		588,792 (65.40)	5,344,817 (59.37)	
Lowest 20%	117,872 (19.03)	207,563 (20.70)		187,093 (20.78)	1,795,221 (19.94)	
Unknown	307 (0.05)	180 (0.02)		1068 (0.12)	6248 (0.07)	
Cohabitation status						
Non-cohabitating	508,676 (82.14)	738,088 (73.60)	<0.0001	733,124 (81.44)	6,639,874 (73.76)	<0.0001
Cohabiting	110,306 (17.81)	264,620 (26.39)		166,048 (18.44)	2,356,278 (26.17)	
Missing	307 (0.05)	180 (0.02)		1068 (0.12)	6248 (0.07)	
History of somatic diseases <sup>a</sup>	29,426 (4.75)	32,506 (3.24)	<0.0001	46,550 (5.17)	271,386 (3.01)	<0.0001
Family history of cardiovascular disease <sup>b</sup>	227,751 (36.78)	392,399 (39.13)	<0.0001	337,832 (37.53)	3,266,253 (36.28)	<0.0001
Type of psychiatric disorders						
1. Non-affective psychotic disorders	16,765 (2.71)	–		24,023 (2.67)	–	
2. Affective psychotic disorders	14,449 (2.33)	–		21,421 (2.38)	–	
3. Substance misuse	107,464 (17.35)	–		161,192 (17.91)	–	
4. Non-psychotic mood disorders	121,439 (19.61)	–		176,450 (19.60)	–	
5. Anxiety and stress related-disorders	200,143 (32.32)	–		291,644 (32.40)	–	
6. Eating disorders	20,136 (3.25)	–		25,665 (2.85)	–	
7. Personality disorders	9049 (1.46)	–		13,575 (1.51)	–	
8. Attention deficit hyperactivity disorder (ADHD)	54,706 (8.83)	–		79,039 (8.78)	–	
9. Autism spectrum disorder (ASD)	18,762 (3.03)	–		26,186 (2.91)	–	
10. Intellectual disability	13,432 (2.17)	–		19,018 (2.11)	–	
11. Others	42,944 (6.93)	–		62,027 (6.89)	–	
Number of psychiatric diagnoses						
One	378,433 (61.11)	–		546,572 (60.71)	–	
Two	130,753 (21.11)	–		191,590 (21.28)	–	
Three or more	110,103 (17.78)	–		162,078 (18.01)	–	


IQR: Interquartile range. P value for difference was calculated by t test for continuous variables, and by Chi-square test for categorical variables. <sup>a</sup>History of somatic diseases included chronic pulmonary disease, connective tissue disease, diabetes, renal diseases, liver diseases, ulcer diseases, and HIV infection/AIDS diagnosed before index date. <sup>b</sup>The difference between exposed patients and unaffected full siblings was due to different number of siblings per exposed patient. The family history of cardiovascular disease was constant within each family.

**Table 1: Characteristics of patients with psychiatric disorders, their unaffected siblings, and matched reference population—a Swedish register-based cohort.**

In the present study, the association between psychiatric disorders and CVD was noted in men and women, across all age groups and calendar periods, and among individuals with or without a history of somatic diseases and family history of CVD. We found an increased risk of incident CVD among most groups of psychiatric patients, except for patients with ASD, possibly due to the young age at diagnosis of ASD (12 years in the present study). Patients with eating disorders, in particular anorexia nervosa, were found to have

the greatest risk increase of CVD, likely due to malnutrition in anorexia nervosa and the cardiovascular implications of energy deprivation and starvation.<sup>34</sup>

We found a direct link between psychiatric disorders and hypertensive disorder, ischemic heart disease, venous thromboembolism, angina pectoris, and stroke. The underlying mechanisms of a higher risk of these CVDs following a psychiatric disorder may involve multiple pathological processes. The increased risk noted immediately after a diagnosis of psychiatric



**Fig. 2: Time-varying hazard ratio for an incident cardiovascular disease among patients with psychiatric disorders, compared to their unaffected full siblings (sibling comparison) or matched reference population (population comparison), by time since psychiatric diagnosis (<1 or  $\geq$ 1 year)\*. A) Sibling comparison. B) Population comparison. \* Time-varying hazard ratios and 95% confidence intervals were derived from flexible parametric survival models, allowing the effect of psychiatric disorder to vary over time. A spline with 5 df was used for the baseline rate, and 3 df was used for the time-varying effect. All models were adjusted for age at index date, sex, educational level, yearly individualized family income, cohabitation status, history somatic diseases, as well as family history of cardiovascular disease (in population comparison).**


disorders may indicate a direct impact of stress-induced hypothalamic activation and changes in sympathetic nervous system, which might contribute to vasoconstriction and increased peripheral vascular resistance, leading to high blood pressure, high heart rate, and low heart rate variability.<sup>35</sup> The inflammatory responses subsequent to severe stress reaction may also promote atherosclerotic formation,<sup>35</sup> contributing to thromboembolism. Psychological stress can also play an important role in individuals with high atherosclerotic plaque burden,<sup>36</sup> triggering, for example, acute cardiac events.<sup>36</sup> In addition, psychotropic medications, e.g., antidepressants, have been shown to have vasoconstrictive effect<sup>37</sup> and complications of QT prolongation.<sup>38</sup> The health behaviors of individuals with psychiatric disorders can as well contribute to the hyperadrenergic state, leading to vasoconstriction and tachycardia.<sup>39</sup> Other lifestyle factors previously associated with psychiatric disorders, such as physical inactivity, smoking, and unhealthy diet, are known risk factors for CVD.<sup>40</sup> In the present study, we also identified several disease pathways that are mediated through other medical conditions, such as sepsis and autoimmune arthritis, suggesting a dysregulation of immune system among patients with psychiatric disorders.<sup>41</sup> These mechanisms may interact in CVD development after diagnosis of psychiatric disorders both in the short and long run. Regardless, because

the disease trajectory analysis captured only two medical conditions following psychiatric disorders, per trajectory, the role of mediating conditions should be further studied.


The strengths of our study include the use of data collected prospectively in a nationwide sample and the complete follow-up, largely minimizing selection and information biases. The sibling comparison alleviates concerns of familial confounding shared between siblings. The nationwide coverage of high-quality health register data complemented with the large sample size enabled comprehensive exploration on various medical conditions to identify disease trajectories following diagnosis of psychiatric disorder. The validation of the observed associations and disease trajectories in two distinct populations lends further support to the robustness and generalizability of our findings.

There are some limitations to be acknowledged. First, psychiatric disorders and CVD were identified through clinical diagnosis from specialized care in Sweden. This likely has led to underestimation of patients with psychiatric disorders and CVD, e.g., patients attending in primary care only. Yet, the replication of the findings in Denmark, where diagnoses from primary care are included, does not suggest a substantial influence of this misclassification on the reported associations. The register diagnoses have not been validated for all the studied






**Fig. 3:** Hazard ratio with 95% confidence interval of different categories of cardiovascular disease among patients with any psychiatric disorder, compared to their unaffected full siblings (sibling comparison) or matched reference population (population comparison), by time since psychiatric diagnosis (<1 or ≥1 year)\*. \*Cox models were stratified by family identifiers in sibling comparison and matching identifiers (birth year and sex) in population comparison, controlling for age at index date, sex, educational level, individualized family income, cohabitation status, history of somatic diseases, and family history of cardiovascular disease (in population comparison). Time since index date was used as underlying time scale.



**Fig. 4:** Hazard ratio with 95% confidence interval of an incident cardiovascular disease among patients with different types of psychiatric disorders, compared to their unaffected full siblings (sibling comparison) or matched population (population comparison), by time since psychiatric diagnosis (<1 or ≥1 year)\*. \*Cox models were stratified by family identifiers in sibling comparison and matching identifiers (birth year and sex) in population comparison, controlling for age at index date, sex, education level, individualized family income, cohabitation status, history of somatic diseases, and family history of cardiovascular disease (in population comparison). Time since index date was used as underlying time scale.



**Fig. 5: Disease trajectories with direct link between psychiatric disorders and incident cardiovascular disease, with hazard ratios derived from the Swedish cohort and Estonian replication cohort\*.** \*This figure illustrates disease trajectories with direct link between psychiatric disorders and incident cardiovascular disease. The ICD codes used to cluster medical conditions are shown in circle. The color of each circle represents the magnitude of the association (hazard ratio) between psychiatric disorders and each cardiovascular disease. The number on each arrow corresponds to the hazard ratio of the association between the two medical conditions of each disease pair.

psychiatric disorders and CVDs. However, previous validation studies have shown good to excellent validity of the diagnoses in both Sweden<sup>42,43</sup> and Denmark.<sup>44,45</sup> Further, given the long study period, the diagnostic criteria for psychiatric disorders and some CVDs might have changed over time. However, as we observed an increased risk of CVD during the up to 30 year follow-up period, we suspect that such change is unlikely to substantially bias our results. Regardless, sub-clinical psychopathology is however not captured in the analysis of either Swedish or Danish data, and warrants separate investigations. Second, patients with psychiatric disorders may have more frequent health care consultations and therefore be more likely to be diagnosed with CVD. However, many of the studied CVD outcomes are severe and require immediate medical attention, which leaves little room for potential surveillance bias. Further, it is possible that some medical conditions (e.g., dermatitis and hypotension) of the disease trajectory analysis may be associated with the treatments for psychiatric disorders and CVD, instead of the diseases. This possibility will need to be delineated further. Finally, given the register-based nature of the present study, we cannot exclude the possibility of residual confounding due to unknown and unmeasured confounders. For instance, although we used sibling comparison to alleviate concern on familial confounding, some lifestyle factors (e.g., smoking, diet, and physical exercise) are not necessarily shared between siblings and could therefore not be controlled for in the sibling comparison.

In conclusion, using large nationwide cohorts of two Nordic countries, we found that patients with psychiatric disorders were at a higher risk of CVD compared to their

full siblings and matched population reference, particularly during the first year after diagnosis. Our study demonstrated several distinct disease trajectories linking psychiatric disorders to CVD. These findings provide evidence for the importance of clinical management of cardiovascular risk among patients with psychiatric disorders, particularly during the first year after diagnosis, and contribute to a better understanding of the mechanisms underlying the development of CVD following psychiatric disorders. Increased surveillance and treatment of CVDs and CVD risk factors should be considered as an integral part of clinical management of newly diagnosed patients with psychiatric disorders, in order to reduce risk of CVD among patients with psychiatric disorders.

**Contributors**

QS, FF, and UV were responsible for the study concept and designed the study. QS, DHM and LBL performed the statistical analysis. QS, FF, and UV drafted the manuscript. QS, DHM, LBL, HS, SK, TA, JB, YL, PFS, WY, KF, PT, YP, OAA, AB, LM, FF and UV analyzed and interpreted the data. QS, FF, and UV had full access to and verified the Swedish data, DHM and AB had full access to and verified the Danish data, and LBL, SK, and LM had full access to and verified the Estonian data in the study. All authors contributed to the writing and revision of the manuscript, and approved the final version. The corresponding author attests that all listed authors meet authorship criteria and that no others meeting the criteria have been omitted. UV is the guarantor.

**Data sharing statement**

The register data are not publicly available due to privacy protection, including General Data Protection Regulation (GDPR). Access to Swedish and Danish register resources is only granted after ethical review by appropriate authorities. Further information on data access to Swedish register data can be found at the Swedish National Board of Health and Welfare (<https://bestalladata.socialstyrelsen.se/>), email: [registerservice@socialstyrelsen.se](mailto:registerservice@socialstyrelsen.se)) and/or Statistics Sweden

(<https://www.scb.se/vara-tjanster/bestall-data-och-statistik/>, email: [scb@scb.se](mailto:scb@scb.se)), and to Danish register data can be found at <https://www.dst.dk/en/TilSalg/Forskningsservice>, or by contacting the senior corresponding authors. Access to data from the Estonian Biobank can only be requested directly from the Estonian Biobank ([releases@ut.ee](mailto:releases@ut.ee), <https://genomics.ut.ee/en/content/estonian-biobank>) upon approval by its scientific committee and the Estonian Committee on Bioethics and Human Research.

#### Declaration of interests

OAA declares receiving grants or contracts from the South-East Norway Health Authority, NIH and KG Jebsen Stiftelsen, receiving consulting fees from Biogen, Cortechs.ai and Milken. OAA gets Speaker's honorarium from Janssen, Lundbeck and Sunovion, and has a patent on Intranasal Administration (US20160310683 A1). OAA participated in advisory board as National PI for JANSSEN trial depression, MAPS trial PTSD and BI trial schizizophrenia. OAA declares having stock at Cortechs.ai. UAV declares receiving support from EPA2023, ISTSS2022 as keynote speaker, and serves on a NordForsk expert committee on Long COVID. FF declares receiving grants from the Swedish Research Council, Swedish Research Council for Health, Workinglife and Welfare, Swedish Cancer Society, European Research Council and the US CDC. FF declares getting payment from Swedish Research Council for grant review. All other authors declare no competing interests.

#### Acknowledgements

This research was supported by EU Horizon 2020 Research and Innovation Action Grant (CoMorMent, Grant nr. 847776 to UAV, PFS, OAA and FF); European Research Council Consolidator grant (StressGene, Grant nr. 726413 to UAV); Icelandic Research fund (to UAV); Swedish Research Council (Vetenskapsrådet, award D0886501 to PFS); US NIMH R01 MH123724 to PFS; the Outstanding Clinical Discipline Project of Shanghai Pudong (Grant No.: PWYgy2021-02) and the Fundamental Research Funds for the Central Universities (to QS); the European Union through the European Regional Development Fund (Project No. 2014-2020.4.01.15-0012 to LM); the Research Council of Norway (RCN grants 223273, 296030, 300309, 324252 to OAA); the South-East Regional Health Authority (grant 2017-112, 2022-073 to OAA); the Stiftelsen Kristian Gerhard Jebsen (grants SKGJ-MED-008 and SKGJ-MED-021 to OAA); and the EEA-RO-NO-2018-0535 (to OAA).

We would like to thank Andres Metspalu and Tõnu Esko for their contribution in data collection for the Estonian Biobank research team.

UV affirms that the manuscript is an honest, accurate, and transparent account of the study being reported; that no important aspects of the study have been omitted; and that any discrepancies from the study as planned have been explained.

#### Appendix A. Supplementary data

Supplementary data related to this article can be found at <https://doi.org/10.1016/j.eclinm.2023.102063>.

#### References

- Momen NC, Plana-Ripoll O, Agerbo E, et al. Association between mental disorders and subsequent medical conditions. *N Engl J Med*. 2020;382:1721. <https://doi.org/10.1056/NEJMoa1915784>. published online April 29.
- Walker ER, McGee RE, Druss BG. Mortality in mental disorders and global disease burden implications: a systematic review and meta-analysis. *JAMA Psychiatry*. 2015;72:334–341.
- Roest AM, Martens EJ, de Jonge P, Denollet J. Anxiety and risk of incident coronary heart disease: a meta-analysis. *J Am Coll Cardiol*. 2010;56:38–46.
- Boscarino JA. A prospective study of PTSD and early-age heart disease mortality among Vietnam veterans: implications for surveillance and prevention. *Psychosom Med*. 2008;70:668–676.
- White JR, Chang CCH, So-Armah KA, et al. Depression and human immunodeficiency virus infection are risk factors for incident heart failure among veterans: veterans aging cohort study. *Circulation*. 2015;132:1630–1638.
- Khambaty T, Stewart JC, Gupta SK, et al. Association between depressive disorders and incident acute myocardial infarction in human immunodeficiency virus-infected adults: veterans aging cohort study. *JAMA Cardiol*. 2016;1:929–937.
- Zivin K, Yosef M, Miller EM, et al. Associations between depression and all-cause and cause-specific risk of death: a retrospective cohort study in the Veterans Health Administration. *J Psychosom Res*. 2015;78:324–331.
- Ebrahimi R, Lynch KE, Beckham JC, et al. Association of post-traumatic stress disorder and incident ischemic heart disease in women veterans. *JAMA Cardiol*. 2021;6:642–651.
- Patten SB, Williams JVA, Lavorato DH, Modgill G, Jetté N, Eliasziw M. Major depression as a risk factor for chronic disease incidence: longitudinal analyses in a general population cohort. *Gen Hosp Psychiatry*. 2008;30:407–413.
- Almas A, Moller J, Iqbal R, Lundin A, Forsell Y. Does depressed persons with non-cardiovascular morbidity have a higher risk of CVD? A population-based cohort study in Sweden. *BMC Cardiovasc Disord*. 2019;19:260.
- Whang W, Kubzansky LD, Kawachi I, et al. Depression and risk of sudden cardiac death and coronary heart disease in women: results from the Nurses' Health Study. *J Am Coll Cardiol*. 2009;53:950–958.
- Huang CJ, Hsieh MH, Hou WH, Liu JC, Jeng C, Tsai PS. Depression, antidepressants, and the risk of coronary heart disease: a population-based cohort study. *Int J Cardiol*. 2013;168:4711–4716.
- Isomura K, Sidorchuk A, Brander G, et al. Risk of specific cardiovascular diseases in obsessive-compulsive disorder. *J Psychiatr Res*. 2021;135:189–196.
- Song H, Fang F, Arnberg FK, et al. Stress related disorders and risk of cardiovascular disease: population based, sibling controlled cohort study. *BMJ*. 2019;365. <https://doi.org/10.1136/bmj.l1255>.
- Rodevand L, Bahrami S, Frei O, et al. Polygenic overlap and shared genetic loci between loneliness, severe mental disorders, and cardiovascular disease risk factors suggest shared molecular mechanisms. *Transl Psychiatry*. 2021;11:1–11.
- Kelishadi R, Poursafa P. A review on the genetic, environmental, and lifestyle aspects of the early-life origins of cardiovascular disease. *Curr Probl Pediatr Adolesc Health Care*. 2014;44:54–72.
- Rokita KI, Dauvermann MR, Donohoe G. Early life experiences and social cognition in major psychiatric disorders: a systematic review. *Eur Psychiatry*. 2018;53:123–133.
- D'Onofrio BM, Lahey BB, Turkheimer E, Lichtenstein P. Critical need for family-based, quasi-experimental designs in integrating genetic and social science research. *Am J Public Health*. 2013;103(Suppl 1):S46–S55.
- Steptoe A, Kivimäki M. Stress and cardiovascular disease. *Nat Rev Cardiol*. 2012;9:360–370.
- Jensen AB, Moseley PL, Oprea TI, et al. Temporal disease trajectories condensed from population-wide registry data covering 6.2 million patients. *Nat Commun*. 2014;5:4022.
- Yang H, Pawitan Y, He W, et al. Disease trajectories and mortality among women diagnosed with breast cancer. *Breast Cancer Res*. 2019;21:95.
- Han X, Hou C, Yang H, et al. Disease trajectories and mortality among individuals diagnosed with depression: a community-based cohort study in UK Biobank. *Mol Psychiatry*. 2021;26:1–11.
- Ludvigsson JF, Andersson E, Ekblom A, et al. External review and validation of the Swedish national inpatient register. *BMC Public Health*. 2011;11:450.
- Ekblom A. The Swedish multi-generation register. In: Dillner J, ed. *Methods in biobanking*. Totowa, NJ: Humana Press; 2011:215–220.
- Richardson DB. An incidence density sampling program for nested case-control analyses. *Occup Environ Med*. 2004;61:e59.
- Nevriana A, Pierce M, Dalman C, et al. Association between maternal and paternal mental illness and risk of injuries in children and adolescents: nationwide register based cohort study in Sweden. *BMJ*. 2020;369. <https://doi.org/10.1136/bmj.m853>.
- Statistikmyndigheten. Longitudinell integrationsdatabas för sjukförsäkrings- och arbetsmarknadsstudier (LISA). Stat. Cent. <https://www.scb.se/vara-tjanster/bestall-data-och-statistik/bestalla-mikrodata/vilka-mikrodata-finns/longitudinella-register/longitudinell-integration-sdatabas-for-sjukforsakrings-och-arbetsmarknadsstudier-lisa/>; 2021. Accessed June 19, 2023.
- Lambert PC, Royston P. Further development of flexible parametric models for survival analysis. *Stata J*. 2009;9:265–290.
- Leitsalu L, Haller T, Esko T, et al. Cohort profile: Estonian Biobank of the Estonian Genome Center, University of Tartu. *Int J Epidemiol*. 2015;44:1137–1147.

- 30 Van der Kooy K, van Hout H, Marwijk H, Marten H, Stehouwer C, Beekman A. Depression and the risk for cardiovascular diseases: systematic review and meta analysis. *Int J Geriatr Psychiatry*. 2007;22:613–626.
- 31 Batelaan NM, Seldenrijk A, Bot M, van Balkom AJLM, Penninx BWJH. Anxiety and new onset of cardiovascular disease: critical review and meta-analysis. *Br J Psychiatry*. 2016;208:223–231.
- 32 Edmondson D, von Känel R. Post-traumatic stress disorder and cardiovascular disease. *Lancet Psychiatry*. 2017;4:320–329.
- 33 Vaccarino V, Goldberg J, Rooks C, et al. Post-traumatic stress disorder and incidence of coronary heart disease: a twin study. *J Am Coll Cardiol*. 2013;62:970–978.
- 34 Sachs KV, Harnke B, Mehler PS, Krantz MJ. Cardiovascular complications of anorexia nervosa: a systematic review. *Int J Eat Disord*. 2016;49:238–248.
- 35 Osborne MT, Shin LM, Mehta NN, Pitman RK, Fayad ZA, Tawakol A. Disentangling the links between psychosocial stress and cardiovascular disease. *Circ Cardiovasc Imaging*. 2020;13:e010931.
- 36 Kivimäki M, Steptoe A. Effects of stress on the development and progression of cardiovascular disease. *Nat Rev Cardiol*. 2018;15:215–229.
- 37 Marano G, Traversi G, Romagnoli E, et al. Cardiologic side effects of psychotropic drugs. *J Geriatr Cardiol*. 2011;8:243–253.
- 38 Beach SR, Celano CM, Sugrue AM, et al. QT prolongation, Torsades de Pointes, and psychotropic medications: a 5-year update. *Psychosomatics*. 2018;59:105–122.
- 39 Akasaki Y, Ohishi M. Cerebrovascular and cardiovascular diseases caused by drugs of abuse. *Hypertens Res*. 2020;43:363–371.
- 40 Nielsen RE, Banner J, Jensen SE. Cardiovascular disease in patients with severe mental illness. *Nat Rev Cardiol*. 2021;18:136–145.
- 41 Dantzer R. Neuroimmune interactions: from the brain to the immune system and vice versa. *Physiol Rev*. 2018;98:477–504.
- 42 Sellgren C, Landén M, Lichtenstein P, Hultman CM, Långström N. Validity of bipolar disorder hospital discharge diagnoses: file review and multiple register linkage in Sweden: validity of register-based bipolar disorder. *Acta Psychiatr Scand*. 2011;124:447–453.
- 43 Ekholm B, Ekholm A, Adolfsson R, et al. Evaluation of diagnostic procedures in Swedish patients with schizophrenia and related psychoses. *Nord J Psychiatry*. 2005;59:457–464.
- 44 Uggerby P, Østergaard SD, Røge R, Correll CU, Nielsen J. The validity of the schizophrenia diagnosis in the Danish Psychiatric Central Research Register is good. *Dan Med J*. 2013;60:A4578.
- 45 Nissen J, Powell S, Koch SV, et al. Diagnostic validity of early-onset obsessive-compulsive disorder in the Danish Psychiatric Central Register: findings from a cohort sample. *BMJ Open*. 2017;7:e017172.